Dynamical basis for drug resistance of HIV-1 protease

BMC Structural Biology

Volumn 11, Issue , 2011, Pages

  Mao, Yi ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; P16 PROTEASE, HUMAN IMMUNODEFICIENCY VIRUS 1;

ARTICLE; CRYSTAL STRUCTURE; DRUG RESISTANCE; ENZYME ACTIVE SITE; LIGAND BINDING; MUTAGENESIS; NONHUMAN; VIRUS MUTATION; ANTIVIRAL RESISTANCE; ARTIFICIAL NEURAL NETWORK; CHEMISTRY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; PROTEIN CONFORMATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; NEURAL NETWORKS (COMPUTER); PROTEIN CONFORMATION;

EID: 79959992520     PISSN: None     EISSN: 14726807     Source Type: Journal    
DOI: 10.1186/1472-6807-11-31     Document Type: Article

References (64)

1. The retroviral enzymes. RA Katz, Annu Rev Biochem 1994 63 133 173 10.1146/annurev.bi.63.070194.001025 7526778 (Pubitemid 24218631)
2. Rational approach to AIDS drug design through structural biology. A Wlodawer, Ann Red Med 2002 53 595 614 10.1146/annurev.med.53.052901.131947 (Pubitemid 34177897)
3. HIV-1 protease inhibitors: a comparative QSAR analysis. A Kurup, SB Mekapati, R Garg, C Hansch, Curr Med Chem 2003 10 1679 1688 10.2174/ 0929867033457070 12871116 (Pubitemid 37038593)
4. Active human immunodeficiency virus protease is required for viral infectivity. NE Kohl, EA Emini, WA Schleif, LJ Davis, JC Heimbach, RA Dixon, EM Scolnick, IS Sigal, Proc Natl Acad Sci USA 1988 85 4686 4690 10.1073/pnas.85.13.4686 3290901
5. Inhibitors of HIV-1 protease: A major success of structureassisted drug design. A Wlodawer, J Vondrasek, Annu Rev Biophys Biomol Struct 1998 27 249 284 10.1146/annurev.biophys.27.1.249 9646869 (Pubitemid 28286016)
6. HIV-1 entry- an expanding portal for drug discovery. WS Blair, Drug Discovery Today 2000 5 183 194 10.1016/S1359-6446(00)01484-7 10790262 (Pubitemid 30211615)
7. In-vivo emergence of hiv-1 variants resistant to multiple protease inhibitors. JH Condra, WA Schleif, OM Blahy, LJ Gabryelski, DJ Graham, JC Quintero, A Rhodes, HL Robbins, E Roth, M Shivaprakash, D Titus, T Yang, H Tepplert, KE Squires, PJ Deutsch, EA EMini, Nature 1995 374 569 571 10.1038/374569a0 7700387
8. Characterization of human immunodeficiency virus type 1 variants with increased resistant to a C2-symmetric protease inhibitor. DD Ho, T Toyoshima, H Mo, DJ Kempf, D Norbeck, CM Chen, NE Wideburg, SK Burt, JW Erickson, MK Singh, J Virol 1994 68 2016 2020 8107264 (Pubitemid 24065777)
9. The active site of HIV-1 protease. PP Mager, Med Res Rev 2001 21 348 353 10.1002/med.1012 11410934 (Pubitemid 32565497)
10. Overcoming HIV-1 resistance to protease inhibitors. E Freire, Drug Discov Today 2006 3 281 286 10.1016/j.ddmec.2006.06.005 (Pubitemid 44356304)
11. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance. S Muzammil, P Ross, E Freire, Biochemistry 2003 42 631 638 10.1021/bi027019u 12534275 (Pubitemid 36133287)
12. Molecular dynamics simulations of 14 HIV protease mutants in complexes with indinavir. XF Chen, IT Weber, RW Harrison, J Mol Model 2004 10 373 381 10.1007/s00894-004-0205-x 15597206 (Pubitemid 40012066)
13. Evaluating the potency of HIV-1 protease drugs to combat resistance. TJ Hou, WA McLaughlin, W Wang, Proteins 2008 71 1163 1174 18004760 (Pubitemid 351564043)
14. Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations. S Muzammil, AA Armstrong, LW Kang, A Jakalian, PR Bonneau, V Schmelmer, LM Amzel, E Freire, J Virol 2007 81 5144 5154 10.1128/JVI.02706-06 17360759 (Pubitemid 46744425)
15. Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. M Prabu-Jeyabalan, E Nalivaika, CA Schiffer, Structure 2002 10 369 381 10.1016/S0969-2126(02)00720-7 12005435 (Pubitemid 34230624)
16. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. K Hertogs, S Bloor, SD Kemp, C Van den Eynde, TM Alcorn, R Pauwels, MV Houtte, S Staszewski, V Miller, BA Larder, AIDS 2000 14 1203 1210 10.1097/00002030- 200006160-00018 10894285 (Pubitemid 30420664)
17. Genotypic testing for human immunodeficiency virus type 1 drug resistance. RW Shafer, Clin Microbiol Rev 2002 15 247 277 10.1128/CMR.15.2.247- 277.2002 11932232 (Pubitemid 34303765)
18. Positive selection detection in 40,000 human immunodeficiency virus (HIV) type 1 sequences automatically identifies drug resistance and positive fitness mutations in HIV protease and reverse transcriptase. L Chen, A Perlina, CJ Lee, J Virol 2004 78 3722 3732 10.1128/JVI.78.7.3722-3732.2004 15016892 (Pubitemid 38568311)
19. Update of the drug resistance mutations in HIV-1: December 2009. VA Johnson, F Brun-Vezinet, B Clotet, HF Gunthard, DR Kuritzkes, D Pillay, JM Schapiro, DD Richman, Top HIV Med 2009 17 138 145 20068260
20. Algorithms for the interpretation of HIV-1 genotypic drug resistance information. J Vercauteren, AM Vandamme, Antivir Res 2006 71 335 342 10.1016/j.antiviral.2006.05.003 16782210 (Pubitemid 44223769)
21. Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype. N Beerenwinkel, B Schmidt, H Walter, R Kaiser, T Lengauer, D Hoffmann, K Korn, J Selbig, Proc Natl Acad Sci USA 2002 99 8271 8276 10.1073/pnas.112177799 12060770 (Pubitemid 34651042)
22. Genotypic predictors of human immunodeficiency virus type 1 drug resistance. SY Rhee, J Taylor, G Wadhera, A Ben-Hur, DL Brutlag, RW Shafer, Proc Natl Acad Sci USA 2006 103 17355 17360 10.1073/pnas.0607274103 17065321 (Pubitemid 44788973)
23. Relating sequence evolution of HIV1-protease to its underlying molecular mechanics. K Hamacher, Gene 2008 422 30 36 10.1016/j.gene.2008.06.007 18590806
24. Detecting and understanding combinatorial mutation patterns responsible for HIV drug resistance. J Zhang, T Hou, W Wang, JS Liu, Proc Natl Acad Sci USA 2010 107 1321 1326 10.1073/pnas.0907304107 20080674
25. Computer prediction of drug resistance mutations in proteins. ZW Cao, LY Han, CJ Zheng, ZL Ji, X Chen, HH Lin, YZ Chen, Drug Discov Today 2005 10 521 529 10.1016/S1359-6446(05)03377-5 15809198
26. Mining complex genotypic features for predicting HIV-1 drug resistance. H Saigo, T Uno, K Tsuda, Bioinformatics 2007 23 2455 2462 10.1093/bioinformatics/ btm353 17698858 (Pubitemid 47423844)
27. Simple linear model provides highly accurate genotypic predictions of HIV-1 drug resistance. K Wang, E Jenwitheesuk, R Samudrala, JE Mittler, Antivir Ther 2004 9 343 352 15259897 (Pubitemid 38878750)
28. Comparative evaluation of three computerized algorithms for prediction of antiretroviral susceptibility from HIV type 1 genotype. M Zazzi, L Romano, G Venturi, RW Shafer, C Reid, F Dal Bello, C Parolin, G Pal PE Valensin, J Antimicrob Chemother 2004 53 356 360 10.1093/jac/dkh021 14688053 (Pubitemid 38239973)
29. Computational study of protein specificity: the molecular basis of HIV-1 protease drug resistance. W Wang, PA Kollman, Proc Natl Acad Sci USA 2001 98 14937 14942 10.1073/pnas.251265598 11752442 (Pubitemid 34013948)
30. Can an optimization/scoring procedure in ligand protein docking be employed to probe drug resistant mutations in proteins? YZ Chen, XL Gu, ZW Cao, J Mol Graph Model 2001 19 560 570 10.1016/S1093-3263(01)00091-2 11552685 (Pubitemid 32823260)
31. Structure-based phenotyping predicts HIV-1 protease inhibitor resistance. MD Shenderovich, RM Kagan, PNR Heseltine, K Ramnarayan, Protein Sci 2003 12 1706 1718 10.1110/ps.0301103 12876320 (Pubitemid 36910051)
32. Predicting drug resistance of the HIV-1 protease using molecular interaction energy components. T Hou, W Zhang, J Wang, W Wang, Proteins 2009 74 837 846 10.1002/prot.22192 18704937
33. Intrinsic dynamics of an enzyme underlies catalysis. EZ Eisenmesser, O Millet, W Labeikovsky, DM Korzhnev, M Wolf-Watz, DA Bosco, JJ Skalicky, LE Kay, D Kern, Nature 2005 438 117 121 10.1038/nature04105 16267559 (Pubitemid 41599831)
34. The role of dynamics in allosteric regulation. D Kern, ERP Zuiderweg, Nature 2003 13 748 757 (Pubitemid 37522151)
35. Global dynamics of proteins: bridging between structure and function. I Bahar, TR Lezon, LW Yang, E Eyal, Annu Rev Biophys 2010 39 23 42 10.1146/annurev.biophys.093008.131258 20192781
36. Large-scale evaluation of dynamically important residues in proteins predicted by the perturbation analysis of a coarse-grained elastic model. W Zheng, M Tekpinar, BMC Struct Biol 2009 9 45 10.1186/1472-6807-9-45 19591676
37. Pump-probe molecular dynamics as a tool for studying protein motion and long range coupling. K Sharp, JJ Skinner, Proteins 2006 65 347 361 10.1002/prot.21146 16933296 (Pubitemid 44454109)
38. Signaling pathways of PDZ2 domain: A molecular dynamics interaction correlation analysis. Y Kong, M Karplus, Proteins 2009 74 145 154 10.1002/prot.22139 18618698
39. Efficient identification of critical residues based only on protein structure by network analysis. MP Cusack, B Thibert, DE Bredesen, G del Rio, PLoS ONE 2007 2 421 10.1371/journal.pone.0000421 17502913
40. Frequency-resolved communication maps for proteins and other nanoscale materials. DM Leitner, J Chem Phys 2009 130 195101 195109 10.1063/1.3130149 19466865
41. Dynamics studies of luciferase using elastic network model: how the sequence distribution of luciferase determines its color. Y Mao, Protein Eng Des Sel 2011 24 341 349 10.1093/protein/gzq109 21159621
42. Finite element solution of the steady-state Smoluchowski equation for rate constant calculations. Y Song, Y Zhang, T Shen, CL Bajaj, JA McCammon, NA Baker, Biophys J 2004 86 2017 2029 10.1016/S0006-3495(04)74263-0 15041644 (Pubitemid 38524394)
43. HIV-1 protease flaps spontaneously close to the correct structure in simulations following manual placement of an inhibitor into the open state. V Hornak, A Okur, RC Rizzo, C Simmerling, J Am Chem Soc 2006 128 2812 2813 10.1021/ja058211x 16506755
44. Closing of the flaps of HIV-1 protease induced by substrate binding: A model of flap closing mechanism in retroviral aspartic proteases. G Toth, A Borics, Biochemistry 2006 45 6606 6614 10.1021/bi060188k 16716071 (Pubitemid 43825361)
45. Coarse-grained molecular dynamics of ligands binding into protein: the case of HIV-1 protease inhibitors. D Li, MS Liu, B Ji, K Hwang, J Chem Phys 2009 130 215102 10.1063/1.3148022 19508101
46. A coarse grained model for the dynamics of flap opening in HIV-1 protease. V Tozzini, JA McCammon, Chem Phys Lett 2005 413 123 128 10.1016/j.cplett.2005.07.075 (Pubitemid 41252378)
47. Flap opening dynamics in HIV-1 protease explored with a coarse-grained model. V Tozzini, J Trylska, C Chang, JA McCammon, J Struct Biol 2007 157 606 615 10.1016/j.jsb.2006.08.005 17029846
48. Residue energy and mobility in sequence to global structure and dynamics of a HIV-1 protease (1DIFA) by a coarse-grained Monte Carlo simulation. RB Pandey, BL Farmer, J Chem Phys 2009 130 044906 10.1063/1.3050106 19191412
49. Accurate and efficient description of protein vibrational dynamics: comparing molecular dynamics and Gaussian models. C Micheletti, P Carloni, A Maritan, Proteins 2004 55 635 645 10.1002/prot.20049 15103627 (Pubitemid 38620088)
50. Cooperative fluctuations of unliganded and substrate-bound HIV-1 protease: A structure-based analysis on a variety of conformations from crystallography and molecular dynamics simulations. N Kurt, WR Scott, CA Schiffer, T Haliloglu, Proteins 2003 51 409 422 10.1002/prot.10350 12696052 (Pubitemid 36528826)
51. Drug resistance in HIV-1 protease: Flexibility assisted mechanism of compensatory mutations. S Piana, P Carloni, U Rothlisberger, Protein Sci 2002 11 2393 2402 12237461
52. HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: possible contributions to drug resistance and a potential new target site for drugs. AL Perryman, JH Lin, JA McCammon, Protein Sci 2004 13 1108 1123 10.1110/ps.03468904 15044738 (Pubitemid 38429231)
53. Analysis of correlated mutations in hiv-1 protease using spectral clustering. Y Liu, E Eyal, I Bahar, Bioinformatics 2008 24 1243 1250 10.1093/bioinformatics/btn110 18375964 (Pubitemid 351659620)
54. Molecular basis for drug resistance in HIV-1 protease. A Ali, RM Bandaranayake, Y Cai, NM King, M Kolli, S Mittal, JF Murzycki, MNL Nalam, EA Nalivaika, A zen, MM Prabu-Jeyabalan, K Thayer, CA Schiffer, Viruses 2010 2 2509 2535 10.3390/v2112509
55. Dynamics of firefly luciferase inhibition by general anesthetics: Gaussian and anisotropic network analyses. A Szarecka, Y Xu, P Tang, Biophys J 2007 93 1895 1905 10.1529/biophysj.106.102780 17513367 (Pubitemid 47437574)
56. Relation between sequence and structure of HIV-1 protease inhibitor complexes: a model system for the analysis of protein flexibility. V Zoete, O Michielin, M Karplus, J Mol Biol 2002 315 21 52 10.1006/jmbi.2001.5173 11771964 (Pubitemid 34722109)
57. Complete mutagenesis of the HIV-1 protease. DD Loeb, R Swanstrom, L Everitt, M Manchester, SE Stamper, CA Hutchison III, Nature 1989 340 397 340 10.1038/340397a0 2666861 (Pubitemid 19191607)
58. Computational study of the resistance shown by the subtype B/HIV-1 protease to currently known inhibitors. A Genoni, G Morra, KM Merz Jr, G Colombo, Biochemistry 2010 49 4283 4295 10.1021/bi100569u 20415450
59. Modeling the site-specific variation of selection patterns along lineages. S Guindon, AG Rodrigo, KA Dyer, JP Huelsenbeck, Proc Natl Acad Sci USA 2004 101 12957 12962 10.1073/pnas.0402177101 15326304 (Pubitemid 39167565)
60. Elastic network models for understanding biomolecular machinery: from enzymes to supramolecular assemblies. C Chennubhotla, AJ Rader, LW Yang, I Bahar, Phys Biol 2005 2 173 S180 10.1088/1478-3975/2/4/S12 16280623 (Pubitemid 41609444)
61. Anisotropy of fluctuation dynamics of proteins with an elastic network model. AR Atilgan, SR Durrel, RL Jernigan, MC Demirel, O Keskin, I Bahar, Biophys J 2001 80 505 515 10.1016/S0006-3495(01)76033-X 11159421
62. An efficient algorithm for large-scale detection of protein families. AJ Enright, S Van Dongen, CA Ouzounis, Nucleic Acids Res 2002 30 1575 1584 10.1093/nar/30.7.1575 11917018 (Pubitemid 34679732)
63. Markov clustering versus affinity propagation for the partitioning of protein interaction graphs. J Vlasblom, SJ Wodak, BMC Bioinformatics 2009 10 99 10.1186/1471-2105-10-99 19331680
64. Evaluation of clustering algorithms for protein-protein interaction networks. S Brohee, J van Helden, BMC Bioinformatics 2006 7 488 10.1186/1471-2105-7-488 17087821 (Pubitemid 44782347)